#USA #Carmel #AI Healthcare #Longevity Medicine #Bioscope.ai

Bioscope.ai: Advancing Personalized Longevity Medicine

In a remarkable leap forward, Bioscope.ai, a leading AI platform for concierge and longevity physicians, has made significant waves in 2026. The company reported over 450% growth in its annual recurring revenue (ARR) and more than 100% in its patient base, alongside a 65% increase in the number of practices adopting its platform since mid-2026. This rapid expansion reflects the increasing demand for advanced tools that empower physicians to have a more comprehensive understanding of their patients' health.

Dr. Don Brown, founder and CEO of Bioscope.ai, emphasized the importance of tailored AI solutions that align with existing medical practices. “Concierge and longevity physicians have mastered their methods, and they need AI that integrates seamlessly with their workflows rather than imposing external models of care,” he stated. This patient-centered philosophy underpins the company's success and growth trajectory.

To further its mission of enhancing personalized healthcare, Bioscope.ai has teamed up with DNAvisit, a strategic partnership aimed at accelerating access to genetic counseling. This collaboration enables physicians to consult on complex genetic information much quicker than before—turning weeks of waiting into days. By integrating this service directly into Bioscope.ai's workflows, doctors can readily request genetic counseling, obtaining insights that help them navigate difficult conversations and make informed decisions about further testing.

The company’s commitment to its growth is evident in its workforce expansion, focusing on increasing its staff by 37% since June. This strategic hiring includes key leadership roles such as Logan Mallory as Chief Marketing Officer and Jessica Sexton as Vice President of Customer Success and Operations. These additions are aimed at enhancing the company's operational efficiency and customer engagement as it scales.

Technologically, Bioscope.ai continues to innovate. This year, new features have rolled out, including MRI-based brain volumetric analyses, an expanded microbiome investigation capability that detects pathogens and antimicrobial resistance markers, and refined pharmacogenomics assessments which provide more insightful polygenic risk scores. Innovations like these are vital as they allow physicians to implement more precise health strategies tailored to each individual's unique health profile.

To showcase these advancements and open up dialogues about personalized healthcare, Dr. Helen Messier, the Chief Medical Officer of Bioscope.ai, is actively participating in prominent events, including the Concierge Medicine Forum and the Eudēmonia Summit. Furthermore, she is set to lead discussions at A4M’s LongevityFest 2026 from December 11 to 13 in Las Vegas, where the company will exhibit its pioneering work.

In a special session titled “What the Clocks Can't Tell You: The Genetic Time Bomb in Your Healthiest Patient,” Dr. Messier aims to uncover the hidden aspects of patient health that are often overlooked, emphasizing the importance of genetic insights within conventional medical frameworks.

As established by one of its pillars, patient privacy and data security are central to Bioscope.ai's operations, with the platform being fully HIPAA-compliant. The array of services provided through the platform not only supports better patient outcomes but also enhances the overall efficiency of physicians within their practices.

In conclusion, Bioscope.ai's growth story in 2026 underscores a transformative shift in how personalized longevity medicine is delivered. With robust technology, strategic partnerships, and a focus on supporting physicians, the company is setting new standards for the future of proactive healthcare. For further information, visit Bioscope.ai.